Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma

Urology

Volumn 63, Issue 6, 2004, Pages 1079-1083

  Zigeuner, Richard ^b   Tsybrovskyy, Oleksiy ^b   Ratschek, Manfred ^b   Rehak, Peter ^b   Lipsky, Katja ^b   Langner, Cord ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; PROTEIN P63;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPROTEINS; PROGNOSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 2942583150     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.01.009     Document Type: Article

References (22)

1. Hall M.C., Womack S., Sagalowsky A.I., et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract a 30-year experience in 252 patients. Urology. 52:1998;594-601
2. Ooms E.C., Anderson W.A., Alons C.L., et al. Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol. 114:1983;140-143
3. Di Como C.J., Urist M.J., Babayan I., et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 8:2002;494-501
4. Yang A., Kaghad M., Wang Y., et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 2:1998;305-316
5. Yang A., Schweitzer R., Sun D., et al. p63 is essential for regenerative proliferation in limb, craniofacial, and epithelial development. Nature. 398:1999;714-718
6. Urist M.J., Di Como C.J., Lu M.L., et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 161:2002;1199-1206
7. Pelosi G., Pasini F., Olsen Stenholm C., et al. p63 immunoreactivity in lung cancer yet another player in the development of squamous cell carcinomas. J Pathol. 198:2002;100-109
8. Hagiwara K., McMenamin M.G., Miura K., et al. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res. 59:1999;4165-4169
9. Park B.J., Lee S.J., Kim J.I., et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res. 60:2000;3370-3374
10. Koga F., Kawakami S., Kumagai J., et al. Impaired DeltaNp63 expression associates with reduced beta-catenin an aggressive phenotype of urothelial neoplasms. Br J Cancer. 88:2003;740-747
11. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature. 351:1991;453-456
12. Nakanishi K., Kawai T., Torikata C. Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. Hum Pathol. 27:1996;1336-1340
13. Rey A., Lara P.C., Redondo E., et al. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter relation to tumor proliferation and survival. Cancer. 79:1997;2178-2185
14. Sobin L.H., Wittekind C. TNM Classification of Malignant Tumors. 6th ed:2002;Wiley-Liss, New York
15. Mostofi F.K., Davies C.J. Histological Typing of Kidney Tumors. 2nd ed:1998;Springer, Berlin
16. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:1998;844-847
17. Bernardini S., Adessi G.L., Billerey C., et al. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol. 162:1999;1496-1501
18. Tiguert R., Bianco F.J. Jr, Oskanian P., et al. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. J Urol. 166:2001;2155-2160
19. Bernardini S., Billerey C., Martin M., et al. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol. 165:2001;42-46
20. Shiina H., Igawa M., Yagi H., et al. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer. Oncology. 53:1996;233-240
21. Shiina H., Igawa M., Shigeno K., et al. Clinical significance of mdm2 and p53 expression in bladder cancer a comparison with cell proliferation and apoptosis. Oncology. 56:1999;239-247
22. Fleshner N., Kapusta L., Ezer D., et al. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol. 164:2000;1177-1182